Literature DB >> 17712931

NIH announces phase III clinical trial of creatine for Parkinson's disease.

Marlene Z Bloom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17712931

Source DB:  PubMed          Journal:  Consult Pharm        ISSN： 0888-5109


× No keyword cloud information.
  5 in total

1.  Mitochondrial therapies for Parkinson's disease.

Authors:  Bobby Thomas; M Flint Beal
Journal:  Mov Disord       Date:  2010       Impact factor: 10.338

Review 2.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

3.  Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

Authors:  Lichuan Yang; Noel Y Calingasan; Elizabeth J Wille; Kerry Cormier; Karen Smith; Robert J Ferrante; M Flint Beal
Journal:  J Neurochem       Date:  2009-03-28       Impact factor: 5.372

Review 4.  Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.

Authors:  Huajun Jin; Arthi Kanthasamy; Anamitra Ghosh; Vellareddy Anantharam; Balaraman Kalyanaraman; Anumantha G Kanthasamy
Journal:  Biochim Biophys Acta       Date:  2013-09-20

5.  The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials.

Authors:  Jia-Jie Mo; Lin-Ying Liu; Wei-Bin Peng; Jie Rao; Zhou Liu; Li-Li Cui
Journal:  BMC Neurol       Date:  2017-06-02       Impact factor: 2.474
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.